Replies to post #166801 on Biotech Values

[oc631]

but how effectively will ABBV be able to compete when other combos come to market that are more convenient/patient friendly which also undercut GILD's pricing?

BMY will eventually be disruptive to ABBV and GILD on pricing in GT1. I'm only going out about a year post-approval with my thinking.